Shares of Agenus Inc. (NASDAQ:AGEN) traded down 3.6% during mid-day trading on Wednesday . The company traded as low as $6.17 and last traded at $6.19, with a volume of 511,766 shares. The stock had previously closed at $6.42.

A number of analysts have recently issued reports on the stock. Jefferies Group restated a “buy” rating on shares of Agenus in a report on Tuesday, August 23rd. HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of Agenus in a report on Sunday, July 31st. Maxim Group restated a “buy” rating and set a $7.00 price target on shares of Agenus in a report on Thursday, July 28th. Finally, Zacks Investment Research upgraded shares of Agenus from a “sell” rating to a “hold” rating in a report on Tuesday, July 5th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. Agenus currently has an average rating of “Buy” and a consensus price target of $10.25.

The company’s market capitalization is $537.99 million. The firm’s 50 day moving average is $5.56 and its 200-day moving average is $4.31.

Agenus (NASDAQ:AGEN) last issued its earnings results on Thursday, July 28th. The company reported ($0.33) earnings per share for the quarter, topping the consensus estimate of ($0.34) by $0.01. The company had revenue of $6.59 million for the quarter, compared to analyst estimates of $5.12 million. Analysts expect that Agenus Inc. will post ($1.27) earnings per share for the current fiscal year.

Agenus Inc (Agenus) is an immuno-oncology company. The Company is engaged in discovering and developing treatments for patients with cancer. Its approaches are driven by platforms and programs, which include antibody discovery platform, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage and AutoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.